Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 24, 2026
Comment on: Hospital-Based Careers in Pediatric Hematology-Oncology: The State of the Field and Future Needs Impact of a Pediatric Onco-Hospitalist Model on Inpatient Oncology Care Delivery.
Journal: Pediatric blood & cancer
Published: May 14, 2026
In-Person and Virtual Adaptation of an Interprofessional Palliative Care Communications Skills Training Course for Pediatric Oncology Clinicians.
Journal: Advances in cancer education and quality improvement
Published: November 21, 2025
Navigating Management of Spindle Cell/Sclerosing Rhabdomyosarcoma With FUS::TFCP2 Fusion in the Era of Targeted Therapy.
Journal: Journal of pediatric hematology/oncology
Published: July 30, 2025
Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors.
Journal: Pediatric blood & cancer
Published: July 18, 2025
Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models.
Journal: Molecular cancer therapeutics
Published: April 22, 2025
TFCP2 Fusion-Positive Rhabdomyosarcomas: A Report of 10 Cases and a Review of the Literature.
Journal: Cancers
Published: March 07, 2025
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 16, 2024
Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group.
Journal: International journal of radiation oncology, biology, physics
Published: July 01, 2024
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
Journal: The Lancet. Oncology
Published: February 05, 2024
Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group.
Journal: Pediatric blood & cancer
Published: January 18, 2024
Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort.
Journal: Rare tumors
Published: January 04, 2024
Last Updated: 09/26/2026